CaaMTech Revenue and Competitors

Location

$22M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • CaaMTech's estimated annual revenue is currently $804k per year.(i)
  • CaaMTech's estimated revenue per employee is $100,500
  • CaaMTech's total funding is $22M.

Employee Data

  • CaaMTech has 8 Employees.(i)
  • CaaMTech grew their employee count by 0% last year.

CaaMTech's People

NameTitleEmail/Phone
1
Founder and CEOReveal Email/Phone
2
Preclinical Program DirectorReveal Email/Phone
3
Technology & MarketingReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$15.1M7519%N/AN/A
#2
$0.8M8-50%N/AN/A
#3
$114M5677%N/AN/A
#4
$19.3M9613%N/AN/A
#5
$5.4M2717%N/AN/A
#6
$17.7M88-45%N/AN/A
#7
$13.9M6910%N/AN/A
#8
$5.4M27-10%N/AN/A
#9
$0.8M80%$22MN/A
#10
$5.4M2729%N/AN/A
Add Company

What Is CaaMTech?

CaaMTech is the foremost drug discovery and lead optimization company focused on engineering psychedelic drugs that meet the standards of modern medicine. CaaMTech is improving the health and happiness of humankind by creating and optimizing psychedelic compounds and formulations through rigorous science and continuous innovation. CaaMTech has carefully selected a diverse group of highly-skilled experts including scientists, healthcare professionals, and technologists at the forefront of their respective fields. Our team members have Ph.D., MBA, and JD degrees from top US and international universities including Princeton, Harvard, and Cornell. CaaMTech’s combined experience connects multiple industries, including branded and generic pharmaceutical companies, natural product innovation, Silicon Valley startups, intellectual property law, consumer product development, manufacturing, and distribution.

keywords:N/A

$22M

Total Funding

8

Number of Employees

$804k

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.7M9-55%N/A
#2
$0.9M100%N/A
#3
$1.7M110%N/A
#4
$1M12-29%N/A
#5
$1.3M13N/AN/A